MX2009003532A - Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. - Google Patents

Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.

Info

Publication number
MX2009003532A
MX2009003532A MX2009003532A MX2009003532A MX2009003532A MX 2009003532 A MX2009003532 A MX 2009003532A MX 2009003532 A MX2009003532 A MX 2009003532A MX 2009003532 A MX2009003532 A MX 2009003532A MX 2009003532 A MX2009003532 A MX 2009003532A
Authority
MX
Mexico
Prior art keywords
stannsoporfin
treatment
low dosages
infant hyperbilirubinemia
hyperbilirubinemia
Prior art date
Application number
MX2009003532A
Other languages
English (en)
Inventor
Benjamin Levinson
Simon Tulloch
Original Assignee
Infacare Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infacare Pharmaceutical Corp filed Critical Infacare Pharmaceutical Corp
Publication of MX2009003532A publication Critical patent/MX2009003532A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos para tratar la hiperbilirrubinemia infantil utilizando estansoporfina. Los métodos de la invención permiten el tratamiento de varias poblaciones de pacientes con dosis de estansoporfina más bajas que las previamente consideradas como efectivas, proporcionando ventajas en la administración terapéutica.
MX2009003532A 2006-10-04 2007-10-04 Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. MX2009003532A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84950906P 2006-10-04 2006-10-04
PCT/US2007/021486 WO2008045378A2 (en) 2006-10-04 2007-10-04 Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin

Publications (1)

Publication Number Publication Date
MX2009003532A true MX2009003532A (es) 2009-06-26

Family

ID=39036883

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003532A MX2009003532A (es) 2006-10-04 2007-10-04 Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.

Country Status (13)

Country Link
US (1) US20080113955A1 (es)
EP (1) EP2076273A2 (es)
JP (1) JP2010505854A (es)
KR (1) KR20090079916A (es)
CN (1) CN101631554A (es)
AU (1) AU2007307112A1 (es)
BR (1) BRPI0717774A2 (es)
CA (1) CA2664934A1 (es)
EA (1) EA200970345A1 (es)
IL (1) IL197839A0 (es)
MX (1) MX2009003532A (es)
NO (1) NO20091580L (es)
WO (1) WO2008045378A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375216B2 (en) 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
US20060222668A1 (en) * 2005-04-01 2006-10-05 Wellspring Pharmaceutical Corporation Stannsoporfin compositions, drug products and methods of manufacture
EA019864B1 (ru) 2006-10-04 2014-06-30 Инфакэар Фармасьютикал Корпорейшн Крупномасштабное производство станнсопорфина высокой чистоты
US20090293326A1 (en) * 2008-05-29 2009-12-03 Bedford Nieves-Cruz Hyperbilirubinemia management calendar
DK2691398T3 (en) 2011-03-30 2017-01-16 Infacare Pharmaceutical Corp Methods for synthesizing metal mesoporphyrins
CA2857153A1 (en) * 2011-12-01 2013-06-06 Infacare Pharmaceutical Corporation Methods for treating hyperbilirubinemia with stannsoporfin
EP3455894A4 (en) * 2016-05-12 2020-03-11 Mallinckrodt Hospital Products IP Limited METHODS OF TREATING HYPER-BILIRUBINEMIA WITH STANNSOPORFIN AND PHOTOTHERAPY
WO2021126855A1 (en) * 2019-12-16 2021-06-24 Mallinckrodt Hospital Products IP Unlimited Company Methods for treating progressive hyperbilirubinemia

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708964A (en) * 1984-02-09 1987-11-24 Chemex Pharmaceuticals Lipoxygenase inhibitors
US4861876A (en) * 1986-11-26 1989-08-29 Wayne State University Hematoporphyrin derivative and method of preparation and purification
US5990363A (en) * 1987-01-02 1999-11-23 Sun Company, Inc. Method for oxidizing alkanes using novel porphyrins synthesized from dipyrromethanes and aldehydes
US4900871A (en) * 1987-01-02 1990-02-13 Sun Refining And Marketing Company Hydrocarbon oxidations catalyzed by iron coordination complexes containing a halogenated ligand
US5062775A (en) * 1989-09-29 1991-11-05 Rocky Mountain Research, Inc. Roller pump in an extra corporeal support system
US5192757A (en) * 1990-12-20 1993-03-09 Glaxo Inc. Cobalt porphyrins
US5817830A (en) * 1992-08-14 1998-10-06 Trustees Of The University Of Pennsylvania Pyrrolic compounds
US5371199B1 (en) * 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
US5493017A (en) * 1992-08-14 1996-02-20 The Trustees Of The University Of Pennsylvania Ring-metalated porphyrins
WO1994028906A1 (en) * 1993-06-14 1994-12-22 The Rockefeller University Treatment of neonatal hyperbilirubin with metalloporphyrin
CA2130853A1 (en) * 1994-08-25 1996-02-26 Svetlana Kudrevich Process for the syntheses of monosulphonated phthalocyanines, naphthobenzoporphyrazines and porphyrins via a modified meerwein reaction
US5912341A (en) * 1995-03-14 1999-06-15 Hoffman/Barrett, L.L.C. Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
WO1997005152A1 (en) * 1995-08-02 1997-02-13 Warner-Lambert Company Amino acid complexes of cobalt (iii) mesoporphyrin ix and cobalt (iii) protoporphyrin ix
US5883246A (en) * 1996-03-07 1999-03-16 Qlt Phototherapeutics, Inc. Synthesis of polypyrrolic macrocycles from meso-substituted tripyrrane compounds
US6004530A (en) * 1996-06-04 1999-12-21 Roche Diagnostics Gmbh Use of metallo-porphyrin conjugates for the detection of biological substances
GB9616353D0 (en) * 1996-08-03 1996-09-11 Secr Defence Metallo-porphyrins
US6124452A (en) * 1997-12-19 2000-09-26 University Of Nebraska-Lincoln Octafluoro-meso-tetraarylporphyrins and methods for making these compounds
DE19706490C1 (de) * 1997-02-19 1998-09-17 Deutsches Krebsforsch Verfahren zur Herstellung von Säureamiden und zur Metallierung von Verbindungen und Verwendung der nach den Verfahren hergestellten Verbindungen
US5886173A (en) * 1997-07-30 1999-03-23 Pharmacyclics, Inc. Metallation of macrocycles with 2,4-dicarbonyl-metal complexes
US6194566B1 (en) * 1997-12-02 2001-02-27 Schering Aktiengesellschaft Process for the production of metalloporphyrin-metal complex conjugates
JP3673888B2 (ja) * 1998-03-09 2005-07-20 独立行政法人科学技術振興機構 ポルフィリン類金属錯体の製造方法
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US5973141A (en) * 1998-11-27 1999-10-26 Miravant Pharmaceuticals, Inc. Method for the demethoxycarbonylation of porphyrinic compounds such as pheophorbides
US6462192B2 (en) * 2001-01-23 2002-10-08 Miravant Pharmaceuticals, Inc. Processes for large scale production of tetrapyrroles
CA2448570A1 (en) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis
US7375216B2 (en) * 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
MXPA04012045A (es) * 2002-06-04 2005-08-16 Wellspring Pharmaceutical Corp Preparacion de compuestos de haluro de metal mesoporfirina.
US20040097481A1 (en) * 2002-11-20 2004-05-20 Benjamin Levinson Water-soluble mesoporphyrin compounds and methods of preparation
US20060222668A1 (en) * 2005-04-01 2006-10-05 Wellspring Pharmaceutical Corporation Stannsoporfin compositions, drug products and methods of manufacture

Also Published As

Publication number Publication date
US20080113955A1 (en) 2008-05-15
NO20091580L (no) 2009-05-04
BRPI0717774A2 (pt) 2014-04-29
EP2076273A2 (en) 2009-07-08
KR20090079916A (ko) 2009-07-22
AU2007307112A1 (en) 2008-04-17
CA2664934A1 (en) 2008-04-17
WO2008045378A2 (en) 2008-04-17
IL197839A0 (en) 2009-12-24
CN101631554A (zh) 2010-01-20
WO2008045378A3 (en) 2008-06-05
JP2010505854A (ja) 2010-02-25
EA200970345A1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
TW200630093A (en) Dose forms
HK1120441A1 (en) Drugs for treatment of ovarian cancer
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
MX2009011444A (es) Titulacion del tapentadol.
SI1913947T1 (sl) Kombinirana terapija za zdravljenje raka
DK1750716T3 (da) Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
MY146533A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
WO2011094260A3 (en) Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal